書誌情報
PR-3. Adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA NSCLC : ADAURA Japan subgroup analysis
Terufumi Kato1, Hirotsugu Kenmotsu2, Shunichi Sugawara3, Yuki Sato4, Kyoichi Okishio5, Hisayoshi Hashimoto6, Kanae Motoyama6, Yohji Itoh7, Ana Bolanos8, Masahiro Tsuboi9
1Department of Thoracic Oncology, Kanagawa Cancer Center, 2Division of Thoracic Oncology, Shizuoka Cancer Center, 3Sendai Kousei Hospital, 4Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 5Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, 6Oncology Research and Development, AstraZeneca, 7Biometrics, AstraZeneca, 8Oncology Research and Development, AstraZeneca, Mississauga, 9Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East
Japanese Journal of Lung Cancer 62(6): 486-486, 2022.
個人会員・法人会員の方（IDが5または10で始まる方）
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
